Valneva surges 30% on upbeat vaccine data

Monday, 18. October 2021 09:36

Shares of Valneva SE skyrocketed over 30% on Monday after the pharmaceutical company released the results of its COVID-19 vaccine study's third phase.

According to the results, the study, conducted on over 4,000 participants, prompted a more robust immune response than that of the AstraZeneca jab.

The Valneva shares jumped 31.58% at 9:19 am CET, selling for €15.4.

Related Links: Valneva SE
Breaking the News / BU